FILE PHOTO: A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed/File Photo
(Reuters) – The U.S. Food and Drug Administration approved Vertex Pharmaceuticals Inc’s combination treatment for a rare condition called cystic fibrosis, the agency said on Monday.
The treatment, Trikafta, is a combination of three drugs that target a defective protein responsible for the life-threatening disease that builds up thick mucus in body parts such as the lungs and digestive tract. (bit.ly/2MxqCrJ)
Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber
Our Standards:The Thomson Reuters Trust Principles.
